Literature DB >> 20880057

Clinical features of liver dysfunction in collagen diseases.

Atsushi Takahashi1, Kazumichi Abe, Junko Yokokawa, Haruyo Iwadate, Hiroko Kobayashi, Hiroshi Watanabe, Atsushi Irisawa, Hiromasa Ohira.   

Abstract

AIM: Liver dysfunction is not rare in patients with collagen disease. We sought to elucidate the clinical features of liver dysfunction in the presence of collagen disease.
METHODS: We analyzed the frequency and causes of liver dysfunction in 607 patients (rheumatoid arthritis [RA], n = 220; systemic lupus erythematosus [SLE], n = 164; systemic sclerosis [SSc], n = 47; Sjögren's syndrome [SjS], n = 44; Behçet's disease, n = 43; polymyositis/dermatomyositis [PM/DM], n = 27; vasculitis syndrome, n = 25; mixed connective tissue disease [MCTD], n = 21; and adult-onset Still's disease [AOSD], n = 16).
RESULTS: Liver dysfunction was observed in 238 (39.2%) of 607 patients showing collagen disease. Patients with AOSD (81.3%), PM/DM (51.9%) and vasculitis syndrome (48.0%) frequently displayed liver dysfunction. Liver dysfunction in collagen diseases results from many causes; drug-induced liver injury (26.1%), fatty liver (7.6%), viral hepatitis (1.3%), autoimmune hepatitis (4.2%), primary biliary cirrhosis (15.9%) and the collagen disease itself (15.5%). Conversely, primary biliary cirrhosis was a leading cause in SSc (76.1%) and SjS (70.0%). Liver dysfunction in collagen disease tended to be mild. In addition, alanine aminotransferase levels correlated positively with ferritin levels in AOSD (R = 0.708, P < 0.05). Moreover, alkaline phosphatase levels correlated positively with C reactive protein levels in vasculitis syndrome (R = 0.833, P < 0.05).
CONCLUSION: Liver dysfunction in the presence of collagen disease has various causes, and dysfunction associated with collagen disease reflects the activity of the collagen disease itself.
© 2010 The Japan Society of Hepatology.

Entities:  

Year:  2010        PMID: 20880057     DOI: 10.1111/j.1872-034X.2010.00707.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  20 in total

Review 1.  Primary biliary cirrhosis in a rheumatoid arthritis patient treated with rituximab, a case-based review.

Authors:  Joaquim Polido-Pereira; Ana Maria Rodrigues; Helena Canhão; Fernando Saraiva; José Alberto Pereira da Silva; João Eurico Fonseca
Journal:  Clin Rheumatol       Date:  2011-10-26       Impact factor: 2.980

2.  Still disease and the liver-an underappreciated association.

Authors:  Kieron B L Lim; Thomas D Schiano
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-12

3.  Clinical characteristics and prognosis of concomitant systemic lupus erythematosus and primary biliary cholangitis.

Authors:  Cheng Cheng; Ziqian Wang; Li Wang; Jiuliang Zhao; Qian Wang; Xinping Tian; Mengtao Li; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2020-10-16       Impact factor: 2.980

4.  Concomitant systemic lupus erythematosus might have a negative impact on the biochemical responses to treatment in patients with primary biliary cholangitis.

Authors:  Xiaoli Fan; Ruoting Men; Ping Ni; Changli Lu; Tengfei Si; Yun Ma; Li Yang
Journal:  Clin Rheumatol       Date:  2019-12-06       Impact factor: 2.980

5.  Liver dysfunction in anti-melanoma differentiation-associated gene 5 antibody-positive patients with dermatomyositis.

Authors:  Takao Nagashima; Yasuyuki Kamata; Masahiro Iwamoto; Hitoaki Okazaki; Noriyoshi Fukushima; Seiji Minota
Journal:  Rheumatol Int       Date:  2019-02-21       Impact factor: 2.631

6.  Involvement of the liver in rheumatic diseases.

Authors:  Hiromasa Ohira; Kazumichi Abe; Atsushi Takahashi
Journal:  Clin J Gastroenterol       Date:  2011-11-26

7.  Activation of farnesoid X receptor attenuates liver injury in systemic lupus erythematosus.

Authors:  Fan Lian; Yu Wang; Jie Chen; Hanshi Xu; Xiuyan Yang; Liuqin Liang; Zhongping Zhan; Yujin Ye; Minhu Chen
Journal:  Rheumatol Int       Date:  2011-03-24       Impact factor: 2.631

8.  Connective tissue diseases in primary biliary cirrhosis: a population-based cohort study.

Authors:  Li Wang; Feng-Chun Zhang; Hua Chen; Xuan Zhang; Dong Xu; Yong-Zhe Li; Qian Wang; Li-Xia Gao; Yun-Jiao Yang; Fang Kong; Ke Wang
Journal:  World J Gastroenterol       Date:  2013-08-21       Impact factor: 5.742

9.  A study of the effects of saliva stimulation by nizatidine on dry mouth symptoms of primary biliary cirrhosis.

Authors:  Tetsu Kikuchi; Katsuharu Hirano; Takuya Genda; Hironori Tsuzura; Shunsuke Sato; Yoshio Kanemitsu; Yutaka Narita; Katsuyori Iijima; Takafumi Ichida
Journal:  World J Hepatol       Date:  2013-03-27

10.  Diffuse Systemic Sclerosis in a Patient with Primary Biliary Cirrhosis and Autoimmune Hepatitis Overlap Syndrome: A Case Report.

Authors:  Hye Sung Han; Ga Ram Ahn; Hyung Joon Kim; Kui Young Park; Kapsok Li; Seong Jun Seo
Journal:  Ann Dermatol       Date:  2019-12-27       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.